Anemia before chemotherapy associated with quality of life in breast cancer patients: A preliminary study

Abstract

performed before and after surgery in 8 of 11 patients. Two cases of primary treatment were one case of recurrence during adjuvant chemotherapy and one case of Stage IV. The most recent treatment in the second-line treatment case is letrozole þ LHRH 2 cases, letrozole 10 cases, Arimidex 2 cases. As for side effects, neutropenia at 2 weeks after the start was G0 1 case, G1 1 case, G2 3 cases, G3 4 cases, G4 7 cases, G3 / 4 appearance rate was 68%. Weight loss was performed in 11 cases (68%). Seven patients were able to continue administration, 43% of the total. The drug dose in the continuous administration cases is 125 mg for 2 cases, 100 mg for 2 cases, and 75 mg for 3 cases. The average duration of continuous administration is currently 11 months. Side effects were severe fatigue G2 and acne-like eruption G2 except for hematological toxicity. Conclusion: 1) PAL was administered to 16 patients and continuous administration was possible in 43%. 2) Hematological toxicity appeared in 68% of G3 / 4 appearance rate P2 À 137 Association of body mass index and gastrointestinal chemotherapy toxicity in breast cancer patients: A preliminary study